This is a highlights summary of an oral session given at the AHSAM 2020 Virtual Annual Scientific Meeting and presented by:

Mitchell Brin, MD
SVP, CSO BOTOX & Neurotoxis; Professor of Neurology
Allergan, an AbbVie company; University of California, Irvine
Irvine, California

The content is produced by Infomedica, the official reporting partner of ASHAM 2020 Virtual Annual Scientific Meeting. The summary text was drafted by Goldcrest Medical Writing, reviewed by Marco Vercellino, MD, an independent external expert, and approved by Jessica Ailani, MD, FAHS and Mark J. Burish, MD, PhD, the scientific editors of the program.

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Carrie Dougherty, MD, FAHS
Associate Professor of Neurology
Fellowship Program Director, Headache Medicine
Assistant Residency Program Director, Neurology
MedStar Georgetown University Hospital

Carrie Dougherty, MD, FAHS
Associate Professor of Neurology
Fellowship Program Director, Headache Medicine
Assistant Residency Program Director, Neurology
MedStar Georgetown University Hospital

Carrie Dougherty, MD, is associate professor of neurology and program director of the headache medicine fellowship at MedStar Georgetown University Hospital in Washington, DC. She is a fellow of the American Headache Society and serves as a member of the Guidelines committee and the Scottsdale Headache Symposium Planning committee. She is secretary of the Southern Headache Society and the Alliance for Headache
Disorders Advocacy.

1. Brin MF, Kirby RS, Slavotinek A, et al. Pregnancy Outcomes Following Exposure to onabotulinumtoxinA. Pharmacoepidemiol Drug Saf 2016;25:179-187.